ADMA News and Press, ADMA Biologics Inc From 12/07/22

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics...

ADMA Biologics ( NASDAQ: ADMA ) is down 7% in after-hours trading after the plasma-derived biologics company announced a public offering of common stock . ADMA ( ADMA ) did not disclose the size of the offering. The company said the proceeds would be used to accelerate...

ADMA Biologics ( NASDAQ: ADMA ), a biotech focused on plasma-derived biologics, added ~27% on Thursday to reach a new 52-week high after the company posted its Q3 2022 financials with a solid revenue beat. Revenue for the quarter reached $41.1M with a ~99% YoY growth...

ADMA Biologics, Inc. (ADMA) Q3 2022 Earnings Conference Call November 9, 2022 04:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - President & CEO Brian Lenz - EVP, CFO & General Ma...

ADMA Biologics press release ( NASDAQ: ADMA ): Q3 GAAP EPS of -$0.08 in-line. Revenue of $41.09M (+98.7% Y/Y) beats by $6.61M . “As we look to 2023, we believe ADMA is well-positioned in its advancement towards profitability. The immunoglobulin (“IG&#...

3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously Gross Profit Growth and Narrowing Net Losses...

ADMA Biologics ( NASDAQ: ADMA ) is scheduled to announce Q3 earnings results on Wednesday, November 9th, after market close. The consensus EPS Estimate is -$0.07 (+46.2% Y/Y) and the consensus Revenue Estimate is $34.48M (+66.7% Y/Y). Over the last 3 months, EPS estima...

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica...

Adma Biologics ( NASDAQ: ADMA ) on Monday said it received U.S. Food and Drug Administration's (FDA) approval for its seventh ADMA BioCenters plasma collection facility in Greensboro, North Carolina. The facility began operations and started source plasma collection in...

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. , Oct. 31, 2022 (GLOBE NEW...